Go Pro
→ This Junior Silver Explorer Is Closing In on Its Biggest Catalyst (From Wall Street Logic) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Appulse Co. stock logo
APL
Appulse
C$0.22
C$0.21
C$0.21
▼
C$0.30
C$3.18M-1.12404726,277 shs500 shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.98
-0.3%		$4.15
$3.75
▼
$7.20
$7.67M1.1814,894 shs10,182 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.70
+10.8%		$0.53
$0.37
▼
$1.50
$5.51M1.4639,098 shs348,422 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Appulse Co. stock logo
APL
Appulse
0.00%0.00%+4.88%-2.27%-17.31%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-0.25%+0.76%+5.29%-17.60%-28.12%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+136.68%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Appulse Co. stock logo
APL
Appulse
C$0.22
C$0.21
C$0.21
▼
C$0.30
C$3.18M-1.12404726,277 shs500 shs
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$3.98
-0.3%		$4.15
$3.75
▼
$7.20
$7.67M1.1814,894 shs10,182 shs
Neuralstem, Inc. stock logo
CUR
Neuralstem
$1.87
-2.1%		$1.06
$1.10
▼
$13.78
$3.93M1.81236,278 shs1.84 million shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.70
+10.8%		$0.53
$0.37
▼
$1.50
$5.51M1.4639,098 shs348,422 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Appulse Co. stock logo
APL
Appulse
0.00%0.00%+4.88%-2.27%-17.31%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-0.25%+0.76%+5.29%-17.60%-28.12%
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00%0.00%0.00%0.00%+136.68%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Appulse Co. stock logo
APL
Appulse
0.00
N/AN/AN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.40
Hold$34.67771.02% Upside
Neuralstem, Inc. stock logo
CUR
Neuralstem
0.00
N/AN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest EVGN, CUR, APL, and BOLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
Evogene Ltd. stock logo
EVGN
Evogene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
5/28/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
Rodman & Renshaw logo
Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$22.00
5/28/2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Appulse Co. stock logo
APL
Appulse
N/AN/AC$0.00 per share61.25C$0.27 per shareN/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.70M0.99N/AN/A$13.81 per share0.29
Neuralstem, Inc. stock logo
CUR
Neuralstem
$260K15.10N/AN/A$6.64 per share0.28
Evogene Ltd. stock logo
EVGN
Evogene
$3.85M1.59N/AN/A$1.37 per share0.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Appulse Co. stock logo
APL
Appulse
C$295.81K-C$0.01N/AN/AN/A-2.36%-2.29%-2.69%N/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$33.38M-$16.33N/AN/AN/A-455.15%-100.89%-48.23%N/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
-$4.93MN/AN/AN/AN/A-39,417.64%-170.51%-110.16%N/A
Evogene Ltd. stock logo
EVGN
Evogene
-$8.48M-$1.39N/AN/AN/A-638.12%-158.82%-80.37%8/18/2026 (Estimated)

Latest EVGN, CUR, APL, and BOLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q2 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27N/AN/AN/A$0.33 millionN/A
8/11/2026Q2 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$3.39-$4.57-$1.18-$4.57$0.50 million$0.01 million
5/16/2026Q1 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27-$0.60-$0.33-$0.60$0.35 million$0.33 million
5/12/2026Q1 2026
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$2.85-$4.31-$1.46-$4.31$1.50 million$0.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Appulse Co. stock logo
APL
Appulse
C$0.60279.07%N/AN/A N/A
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/AN/AN/AN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Appulse Co. stock logo
APL
Appulse
N/A
106.21
0.55
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.98
3.51
3.51
Neuralstem, Inc. stock logo
CUR
Neuralstem
N/A
2.53
2.53
Evogene Ltd. stock logo
EVGN
Evogene
N/A
2.79
2.76

Institutional Ownership

CompanyInstitutional Ownership
Appulse Co. stock logo
APL
Appulse
0.09%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
Neuralstem, Inc. stock logo
CUR
Neuralstem
38.30%
Evogene Ltd. stock logo
EVGN
Evogene
10.40%

Insider Ownership

CompanyInsider Ownership
Appulse Co. stock logo
APL
Appulse
68.55%
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
9.40%
Neuralstem, Inc. stock logo
CUR
Neuralstem
5.38%
Evogene Ltd. stock logo
EVGN
Evogene
7.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Appulse Co. stock logo
APL
Appulse
N/A14.77 millionN/ANot Optionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
901.92 million1.74 millionNot Optionable
Neuralstem, Inc. stock logo
CUR
Neuralstem
62.10 millionN/ANot Optionable
Evogene Ltd. stock logo
EVGN
Evogene
1408.72 million8.07 millionNo Data

Recent News About These Companies

Evogene (NASDAQ:EVGN) Stock Price Passes Below 200 Day Moving Average - Here's Why
August 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30940153
Evogene Schedules Second Quarter 2026 Financial Results Release
July 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2026-financial-results-release-302838854.html
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-ltd-and-eleo-inc-announce-collaboration-to-develop-next-generation-oral-small-molecule-pcsk9-pathway-inhibitors-for-hyperlipidemia-and-cardiovascular-diseases-302832108.html
Evogene Expands ATM Offering as Shareholder Activism Escalates
July 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/evogene-expands-atm-offering-as-shareholder-activism-escalates?utm_source=marketbeat.com&utm_medium=referral
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
July 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/agplenus-launches-novel-ai-model-for-predicting-antifungal-potency-expanding-chempass-ai-for-ag-capabilities-302826355.html
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-and-tel-aviv-universitys-blavatnik-center-for-drug-discovery-announce-joint-initiative-to-accelerate-ai-driven-small-molecule-drug-discovery-302820619.html
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-announces-major-milestone-in-its-collaboration-with-google-cloud-advancing-chempass-ai-toward-autonomous-small-molecule-discovery-and-optimization-302808856.html
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P.
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/evogene-sets-up-2-9-million-at-the-market-share-offering-with-a-g-p?utm_source=marketbeat.com&utm_medium=referral
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-302795111.html
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-announces-successful-completion-of-phase-1-clinical-study-of-bmc128-a-rationally-designed-live-bacterial-product-in-combination-with-nivolumab-by-its-subsidiary-biomica-302788213.html
Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript
May 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/evogene-ltd-nasdaqevgn-q1-2026-earnings-call-transcript-1766463/
Evogene Earnings Call: AI Momentum vs. Cash Strain
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/evogene-earnings-call-ai-momentum-vs-cash-strain?utm_source=marketbeat.com&utm_medium=referral
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
May 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4907071-evogene-ltd-evgn-q1-2026-earnings-call-transcript
Evogene: EPS übertrifft Schätzungen um 0,26 $ - Umsatz schlechter als erwartet
May 20, 2026  |  de.investing.comhttps://de.investing.com/news/earnings/evogene-eps-ubertrifft-schatzungen--um-026---umsatz-schlechter-als-erwartet-3491344
Evogene Reports First Quarter 2026 Financial Results
May 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-reports-first-quarter-2026-financial-results-302777474.html
Evogene Q1 2026 earnings preview
May 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/evogene-q1-2026-earnings-preview/ar-AA23A1Ry
Evogene to Present at the 24th Schrödinger European User Group Meeting
May 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-to-present-at-the-24th-schrodinger-european-user-group-meeting-302769386.html
Evogene Schedules First Quarter 2026 Financial Results Release
May 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2026-financial-results-release-302765447.html
Evogene (EVGN) price target increased by 28.57% to 2.30
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/evogene-evgn-price-target-increased-by-28-57-to-2-30/ar-AA21XaL8
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
April 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification-302732572.html

Media Sentiment Over Time

Top Headlines

View All Headlines
A brass balance scale weighs stacks of financial documents on a desk, with a stock candlestick chart in the background.
3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
By Nathan Reiff | August 2, 2026
Illustration of a chip-like structure displaying AMD and Anthropic logos connected by colorful data streams in a server room.
AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle
By Jeffrey Neal Johnson | July 23, 2026
Amazon-branded package carried by a delivery drone inside a warehouse, highlighting Amazon logistics and tech momentum.
Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
By Sam Quirke | July 31, 2026
Illustration of the Apple logo glowing on a circuit board encased in a translucent box against a digital backdrop.
Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
By Sam Quirke | July 15, 2026
Bloom Energy logo displayed beside a row of fuel cell units and a large industrial building under a cloudy sky.
Why Bloom Energy May Be the Most Important AI Infrastructure Stock
By Thomas Hughes | July 29, 2026
Appulse stock logo

Appulse CVE:APL

C$0.22 0.00 (0.00%)
As of 07/20/2026

Appulse Corporation, through its subsidiaries, sells new and refurbished centrifuge machines and parts in Canada, the United States, and internationally. The company is also involved in the rental of centrifuge equipment; and provision of maintenance services, consulting, and design advisory services to industries, as well as machining services for equipment repairs. In addition, it offers value-added services; and manufactures parts using machining and milling equipment. The company provides its products and services for food and beverage processing, and environmental applications, as well as serves the oil and gas, refinery, marine processing, and pharmaceutical industries. Appulse Corporation is based in Calgary, Canada.

Bolt Biotherapeutics stock logo

Bolt Biotherapeutics NASDAQ:BOLT

$3.98 -0.01 (-0.25%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$3.83 -0.15 (-3.67%)
As of 08/11/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Neuralstem stock logo

Neuralstem NASDAQ:CUR

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Evogene stock logo

Evogene NASDAQ:EVGN

$0.70 +0.07 (+10.79%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$0.66 -0.04 (-5.07%)
As of 06:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas